Multidrug resistance proteins preferentially regulate natriuretic peptide‐driven cGMP signalling in the heart and vasculature
Open Access
- 13 July 2021
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 179 (11), 2443-2459
- https://doi.org/10.1111/bph.15593
Abstract
Background and Purpose cGMP underpins the bioactivity of NO and natriuretic peptides and is key to cardiovascular homeostasis. cGMP-driven responses are terminated primarily by PDEs, but cellular efflux via multidrug resistance proteins (MRPs) might contribute. Herein, the effect of pharmacological blockade of MRPs on cGMP signalling in the heart and vasculature was investigated in vitro and in vivo. Experimental Approach Proliferation of human coronary artery smooth muscle cells (hCASMCs), vasorelaxation of murine aorta and reductions in mean arterial BP (MABP) in response to NO donors or natriuretic peptides were determined in the absence and presence of the MRP inhibitor MK571. The ability of MRP inhibition to reverse morphological and contractile deficits in a murine model of pressure overload-induced heart failure was also explored. Key Results MK571 attenuated hCASMC growth and enhanced the anti-proliferative effects of NO and atrial natriuretic peptide (ANP). MRP blockade caused concentration-dependent relaxations of murine aorta and augmented responses to ANP (and to a lesser extent NO). MK571 did not decrease MABP per se but enhanced the hypotensive actions of ANP and improved structural and functional indices of disease severity in experimental heart failure. These beneficial actions of MRP inhibition were associated with a greater intracellular:extracellular cGMP ratio in vitro and in vivo. Conclusions and Implications MRP blockade promotes the cardiovascular functions of natriuretic peptides in vitro and in vivo, with more modest effects on NO. MRP inhibition may have therapeutic utility in cardiovascular diseases triggered by dysfunctional cGMP signalling, particularly those associated with altered natriuretic peptide bioactivity.Keywords
Funding Information
- British Heart Foundation (FS/13/58/30648, RG/16/7/32357)
- Medical Research Council Canada (PhD studentship)
This publication has 74 references indexed in Scilit:
- Transporters in human platelets: physiologic function and impact for pharmacotherapyBlood, 2012
- Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase IEuropean Heart Journal, 2011
- Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytesThe FASEB Journal, 2011
- Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathwayCardiovascular Research, 2011
- Mammalian multidrug-resistance proteins (MRPs)Essays in Biochemistry, 2011
- Inhibition of MRP4 prevents and reverses pulmonary hypertension in miceJCI Insight, 2011
- Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferationJCI Insight, 2008
- Reciprocal regulation of human soluble and particulate guanylate cyclasesin vivoBritish Journal of Pharmacology, 2006
- Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac MyocytesCirculation, 2006